BioCentury
ARTICLE | Clinical News

GSK vaccine could provide alternative for TB

October 29, 2019 11:16 PM UTC
Updated on Oct 29, 2019 at 11:21 PM UTC

In line with two-year data, GSK reported that its pulmonary tuberculosis vaccine lowered the incidence of active disease by 50% at three years. M72/AS01E could provide an alternative to the only approved TB vaccine, Bacillus Calmette-Guerin (BCG), which has variable effectiveness protecting against pulmonary disease in adolescents and adults.

In final results published Tuesday in The New England Journal of Medicine from a Phase IIb trial conducted by GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and the International AIDS Vaccine Initiative, 13 participants who received the M72/AS01E vaccine candidate developed pulmonary tuberculosis vs. 26 in the placebo group by year three (95% CI: 0.26, 0.98; p=0.04). ...